The latest price target for Theriva Biologics (AMEX:TOVX) was reported by Maxim Group on November 13, 2024. The analyst firm set a price target for $6.00 expecting TOVX to rise to within 12 months (a possible 426.32% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Theriva Biologics (AMEX:TOVX) was provided by Maxim Group, and Theriva Biologics maintained their buy rating.

There is no last upgrade for Theriva Biologics

There is no last downgrade for Theriva Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theriva Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theriva Biologics was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Theriva Biologics (TOVX) rating was a maintained with a price target of $25.00 to $6.00. The current price Theriva Biologics (TOVX) is trading at is $1.14, which is out of the analyst’s predicted range.